Global Acute Vulvovaginal Candidiasis Treatment Market to Surpass US$ 397.8 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global acute vulvovaginal candidiasis treatment market is estimated to be valued at US$ 308.0 million in 2020 and is expected to exhibit a CAGR of 3.0% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Acute Vulvovaginal Candidiasis Treatment Market:

Key trends in the market include increasing prevalence of acute vulvovaginal candidiasis, increasing research and development activities, and others.

Market players are involved in publishing positive clinical trial results for the treatment of vulvovaginal candidiasis in the peer-reviewed journal, which is expected to drive growth of the acute vulvovaginal candidiasis treatment market over the forecast period. For instance, on August 26, 2020, Mycovia Pharmaceuticals, Inc. published positive results for the Phase II clinical trials, which was conducted for testing the safety and efficacy of their oral drug candidate oteseconazole (VT-1161), an antifungal drug, for the treatment of vulvovaginal candidiasis.

Increasing research and development activities for developing new treatment for vulvovaginal candidiasis is expected to drive the global acute vulvovaginal candidiasis treatment market growth over the forecast period. For instance, on April 29, 2020, researchers at the University of Bristol, U.K. found that C12AHL, a chemical released from the bacterial species Pseudomonas aeruginosa, acts as the chemical signal for Candida species. This signal improves the activity of fluconazole against the candida species causing vulvovaginal candidiasis. According to the researchers, the signal molecule can be packaged in small lipid molecules and can be delivered along with Fluconazole tablets.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4315

Market players are involved in commencing the manufacturing and distribution agreement with other companies for the development and distribution of the drugs in specific regions, in order to expand the customer base, which is expected to drive growth of the market over the forecast period. For instance, in 2019, Mycovia Pharmaceuticals, Inc. entered into a manufacturing and distribution agreement with Jiangsu Hengrui Medicine Co. for the development and commercialization of oteseconazole, an antifungal drug for the treatment of vulvovaginal candidiasis, in China, including mainland China, Hong Kong, Macau, and Taiwan. Moreover, in 2019, Mycovia Pharmaceuticals, Inc. also entered into a manufacturing and distribution agreement with Gedeon Richter Plc., for the development and commercialization of oteseconazole in Europe, Russia, the Commonwealth of Independent States, Latin America, and Australia.

Key Market Takeaways:

The global acute vulvovaginal candidiasis treatment market is expected to exhibit a CAGR of 3.0% during the forecast period (2020-2027), owing to increasing research and development activities. For instance, in 2019, Scynexis, Inc. initiated Phase III clinical trials for testing the safety and efficacy of the drug, oral ibrexafungerp (SCY-078), a glucan synthase inhibitor class with a novel triterpenoid structure.

Among regions, North America is expected to hold a dominant position in the global acute vulvovaginal candidiasis treatment market over the forecast period, owing to increasing prevalence of acute vulvovaginal candidiasis treatment in this region. For instance, according to the Centers for Disease Control and Prevention (CDC): November 3, 2020, vulvovaginal candidiasis is the second common type of infection found in the U.S. after bacterial vaginal infections.

Key Market Players:

Key players operating in the global acute vulvovaginal candidiasis treatment market include Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4315

Market Segmentation:

• By Drug Type:
  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others
• By Route of Administration:
  • Oral
  • Intravenous
  • Topical
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005263/en/